ACH-702

ACH-702 is a novel **isothiazoloquinolone** antibacterial agent that inhibits bacterial DNA replication by targeting **DNA gyrase** and **topoisomerase IV**. Developed by Achillion Pharmaceuticals, it exhibits potent broad-spectrum activity against Gram-positive and Gram-negative pathogens, including multidrug-resistant strains such as MRSA, VRE, and extensively drug-resistant *Mycobacterium tuberculosis* (XDR-TB), as well as nontuberculous mycobacteria like *M. fortuitum* and *M. avium* complex. It demonstrates bactericidal effects against nondividing bacteria and biofilms, with low MIC values (e.g., 0.0625-0.125 μg/ml against *M. tuberculosis*), and comparable intracellular activity to rifampin and moxifloxacin in macrophage models.[1][2][3][8][9]